Zoledronic Acid (Reclast®) Injection

Zoledronic acid (Reclast) is covered for FDA‑approved uses (treatment/prevention of postmenopausal osteoporosis, treatment of osteoporosis in men, glucocorticoid‑induced osteoporosis, Paget’s disease) and compendial osteogenesis imperfecta, and is not supported if the specific indication and policy criteria are not met. Approval requires documentation of diagnosis, BMD/T‑scores or a fragility fracture, usually a prior 12‑month oral bisphosphonate trial (or documented intolerance/inability), adherence to dosing/frequency limits (5 mg IV yearly for treatment, 5 mg IV every 2 years for prevention; Paget: single 5 mg dose; OI: ≤0.05 mg/kg no more often than q3 months) and evidence of response for reauthorization.

"Treatment and prevention of osteoporosis in postmenopausal women"

Sign up to see full coverage criteria, indications, and limitations.